Literature DB >> 23225702

Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin.

Kyohei Yumura1, Mihoko Ui, Hirofumi Doi, Takao Hamakubo, Tatsuhiko Kodama, Kouhei Tsumoto, Akira Sugiyama.   

Abstract

The defining property of core streptavidin (cSA) is not only its high binding affinity for biotin but also its pronounced thermal and chemical stability. Although potential applications of these properties including therapeutic methods have prompted much biological research, the high immunogenicity of this bacterial protein is a key obstacle to its clinical use. To this end, we have successfully constructed hypoimmunogenic cSA muteins in a previous report. However, the effects of these mutations on the physicochemical properties of muteins were still unclear. These mutations retained the similar electrostatic charges to those of wild-type (WT) cSA, and functional moieties with similar hydrogen bond pattern. Herein, we performed isothermal titration calorimetry, differential scanning calorimetry, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis to gain insight into the physicochemical properties and functions of these modified versions of cSA. The results indicated that the hypoimmunogenic muteins retained the biotin-binding function and the tetramer structure of WT cSA. In addition, we discuss the potential mechanisms underlying the success of these mutations in achieving both immune evasion and retention of function; these mechanisms might be incorporated into a new strategy for constructing hypoimmunogenic proteins.
Copyright © 2013 The Protein Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23225702      PMCID: PMC3588917          DOI: 10.1002/pro.2203

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  35 in total

1.  Fast and accurate side-chain topology and energy refinement (FASTER) as a new method for protein structure optimization.

Authors:  Johan Desmet; Jan Spriet; Ignace Lasters
Journal:  Proteins       Date:  2002-07-01

Review 2.  Practical considerations in refolding proteins from inclusion bodies.

Authors:  Kouhei Tsumoto; Daisuke Ejima; Izumi Kumagai; Tsutomu Arakawa
Journal:  Protein Expr Purif       Date:  2003-03       Impact factor: 1.650

3.  Anchor profiles of HLA-specific peptides: analysis by a novel affinity scoring method and experimental validation.

Authors:  Johan Desmet; Geert Meersseman; Nathalie Boutonnet; Jurgen Pletinckx; Krista De Clercq; Maja Debulpaep; Tessa Braeckman; Ignace Lasters
Journal:  Proteins       Date:  2005-01-01

4.  Avidin and streptavidin.

Authors:  N M Green
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

5.  Postsecretory modifications of streptavidin.

Authors:  E A Bayer; H Ben-Hur; Y Hiller; M Wilchek
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

6.  High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.

Authors:  J Willuda; A Honegger; R Waibel; P A Schubiger; R Stahel; U Zangemeister-Wittke; A Plückthun
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

7.  Extremely high thermal stability of streptavidin and avidin upon biotin binding.

Authors:  M González; C E Argaraña; G D Fidelio
Journal:  Biomol Eng       Date:  1999-12-31

8.  Reduction of immunogenicity by covalent modification of murine and rabbit immunoglobulins with oxidized dextrans of low molecular weight.

Authors:  R Fagnani; M S Hagan; R Bartholomew
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

9.  Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes.

Authors:  Y Laroche; S Heymans; S Capaert; F De Cock; E Demarsin; D Collen
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

10.  Reduced antibody response to streptavidin through site-directed mutagenesis.

Authors:  D L Meyer; J Schultz; Y Lin; A Henry; J Sanderson; J M Jackson; S Goshorn; A R Rees; S S Graves
Journal:  Protein Sci       Date:  2001-03       Impact factor: 6.725

View more
  15 in total

1.  Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Authors:  Damian J Green; Shani L Frayo; Yukang Lin; Donald K Hamlin; Darrell R Fisher; Sofia H L Frost; Aimee L Kenoyer; Mark D Hylarides; Ajay K Gopal; Theodore A Gooley; Johnnie J Orozco; Brian G Till; Shyril O'Steen; Kelly D Orcutt; D Scott Wilbur; K Dane Wittrup; Oliver W Press
Journal:  Cancer Res       Date:  2016-09-02       Impact factor: 12.701

Review 2.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

Review 3.  Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.

Authors:  Qi Yang; Christina L Parker; Justin D McCallen; Samuel K Lai
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

4.  CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

Authors:  Damian J Green; Shyril O'Steen; Yukang Lin; Melissa L Comstock; Aimee L Kenoyer; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Margaret Nartea; Mark D Hylarides; Ajay K Gopal; Theodore A Gooley; Johnnie J Orozco; Brian G Till; Kelly D Orcutt; K Dane Wittrup; Oliver W Press
Journal:  Blood       Date:  2017-11-20       Impact factor: 22.113

Review 5.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.

Authors:  Nicolas Bertrand; Jun Wu; Xiaoyang Xu; Nazila Kamaly; Omid C Farokhzad
Journal:  Adv Drug Deliv Rev       Date:  2013-11-22       Impact factor: 15.470

6.  The Crystal Structure of Monovalent Streptavidin.

Authors:  Min Zhang; Sangita Biswas; Wenbin Deng; Hongjun Yu
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

7.  Disruption of cell adhesion by an antibody targeting the cell-adhesive intermediate (X-dimer) of human P-cadherin.

Authors:  Shota Kudo; Jose M M Caaveiro; Satoru Nagatoishi; Takamitsu Miyafusa; Tadashi Matsuura; Yukio Sudou; Kouhei Tsumoto
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

8.  mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting.

Authors:  Jason J Lohmueller; James D Ham; Michael Kvorjak; Olivera J Finn
Journal:  Oncoimmunology       Date:  2017-10-26       Impact factor: 8.110

Review 9.  Influence of protein fold stability on immunogenicity and its implications for vaccine design.

Authors:  Sandra Scheiblhofer; Josef Laimer; Yoan Machado; Richard Weiss; Josef Thalhamer
Journal:  Expert Rev Vaccines       Date:  2017-03-24       Impact factor: 5.217

10.  Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes.

Authors:  Paul R Moody; Edward J Sayers; Johannes P Magnusson; Cameron Alexander; Paola Borri; Peter Watson; Arwyn T Jones
Journal:  Mol Ther       Date:  2015-09-28       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.